Arvenum 500 mg 60 coated tablets

Arvenum 500 mg 60 coated tablets is a vasoprotective and venotonic indicated for the symptomatic treatment of venous insufficiency and capillary fragility . Thanks to its formulation based on micronized purified flavonoid fraction (450 mg of diosmin and 50 mg of flavonoids expressed in hesperidin per tablet), Arvenum 500 mg promotes the well-being of venous circulation and microcirculation , proving particularly useful in cases of heavy legs , swelling and symptoms related to poor circulation.

Arvenum 500 mg is also indicated for the symptomatic treatment of acute hemorrhoidal crisis , helping to quickly relieve the discomfort associated with hemorrhoids . The coated tablets are easy to take and ensure optimal release of the active ingredients, ensuring a targeted and prolonged action. The presence of diosmin and flavonoids makes this product particularly effective in strengthening the walls of blood vessels and reducing capillary permeability, thus improving capillary resistance and venous functionality.

Arvenum 500 mg 60 coated tablets is the ideal choice for those seeking reliable support against venous circulation disorders and for the treatment of symptoms of venous insufficiency and hemorrhoids . Thanks to its effectiveness and specific formulation, it represents a valid ally for the well-being of the legs and microcirculation.

ACTIVE INGREDIENTS

Active substances contained in Arvenum 500 mg 60 coated tablets - What is the active substance of Arvenum 500 mg 60 coated tablets?

Each film-coated tablet contains 500 mg of micronized purified flavonoid fraction consisting of 450 mg of diosmin and 50 mg of flavonoids expressed as hesperidin. For the full list of excipients, see section 6.1.

EXCIPIENTS

Composition of Arvenum 500 mg 60 coated tablets - What does Arvenum 500 mg 60 coated tablets contain?

Sodium starch glycolate, microcrystalline cellulose, gelatin, glycerin, hypromellose, sodium lauryl sulphate, yellow iron oxide E 172, red iron oxide E 172, titanium dioxide, macrogol 6000, magnesium stearate, talc.

DIRECTIONS

Therapeutic indications Arvenum 500 mg 60 coated tablets - Why is Arvenum 500 mg 60 coated tablets used? What is it used for?

Symptoms attributable to venous insufficiency; states of capillary fragility Symptomatic treatment of acute hemorrhoidal crisis.

CONTRAINDICATIONS AND SIDE EFFECTS

Contraindications Arvenum 500 mg 60 coated tablets - When should Arvenum 500 mg 60 coated tablets not be used?

Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1.

DOSAGE

Quantity and method of taking Arvenum 500 mg 60 coated tablets - How to take Arvenum 500 mg 60 coated tablets?

Dosage Venous insufficiency (including haemorrhoidal plexus) and capillary fragility The recommended dose is 2 tablets to be taken in two administrations per day. Do not exceed the maximum daily dose. Acute haemorrhoidal crisis The recommended dose is 3 tablets twice a day during the first 4 days of treatment; in the following 3 days the daily dose is 4 tablets in 2 administrations. Do not exceed the maximum daily dose. Method of administration Take the tablets with the two main meals. Duration of treatment The treatment should not be continued beyond 7 days. In the absence of a therapeutic response, reassess the situation.

CONSERVATION

Storage Arvenum 500 mg 60 coated tablets - How to store Arvenum 500 mg 60 coated tablets?

This medicinal product does not require any special storage conditions.

WARNINGS

Warnings Arvenum 500 mg 60 coated tablets - About Arvenum 500 mg 60 coated tablets it is important to know that:

Important information about some of the ingredients Arvenum contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodium-free'.

INTERACTIONS

Interactions Arvenum 500 mg 60 coated tablets - Which medicines or foods can modify the effect of Arvenum 500 mg 60 coated tablets?

No interaction studies have been performed. No clinically relevant drug interactions have been reported so far from post-marketing experience with the product.

SIDE EFFECTS

Like all medicines, Arvenum 500 mg 60 coated tablets can cause side effects - What are the side effects of Arvenum 500 mg 60 coated tablets?

The following adverse reactions or effects have been reported and have been classified according to the following frequency: very common (≥1/10); common (≥1/100, <1/10); uncommon (≥1/1,000, <1/100); rare (≥1/10,000, <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data). Nervous system disorders Rare: dizziness, headache, malaise Gastrointestinal disorders Common: diarrhoea, dyspepsia, nausea, vomiting Uncommon: colitis Not known: abdominal pain Skin and subcutaneous tissue disorders Rare: rash, pruritus, urticaria Not known: oedema of the face, lips, eyelid; Quincke's edema Blood and lymphatic system disorders Not known: thrombocytopenia Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https://www.aifa.gov.it/content/segnalazioni-reazioni-avverse.

OVERDOSE

Overdose Arvenum 500 mg 60 coated tablets - What are the risks of Arvenum 500 mg 60 coated tablets in case of overdose?

Symptoms There is limited experience with overdose of Arvenum. The most frequently reported adverse events in overdose cases were gastrointestinal events (such as diarrhoea, nausea, abdominal pain) and skin events (such as pruritus, rash). Management Management of overdose should consist of treatment of clinical symptoms.

PREGNANCY AND BREASTFEEDING

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Arvenum 500 mg 60 coated tablets.

Pregnancy There are no or limited amount of data from the use of micronized purified flavonoid fraction in pregnant women. Animal studies do not indicate reproductive toxicity (see section 5.3). As a precautionary measure, it is preferable to avoid the use of Arvenum during pregnancy. Breast- feeding It is not known whether the active substance/metabolites are excreted in human milk. A risk to the newborns/infants cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from therapy with Arvenum taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman. Fertility Reproductive toxicity studies have shown no effect on fertility in either male or female rats (see section 5.3).

DRIVING AND USE OF MACHINERY

Taking Arvenum 500 mg 60 coated tablets before driving or using machines - Does Arvenum 500 mg 60 coated tablets affect driving or using machines?

No studies have been conducted to evaluate the effect of the flavonoid fraction on the ability to drive or use machines.